A new look at the role of p53 in leukemia cell sensitivity to chemotherapy

Leukemia

Volumn 11, Issue 11, 1997, Pages 1842-1849

  Trepel, M ^a   Scheding, S ^a   Groscurth, P ^b   Horny, H P ^c   Malipiero, U ^d   Brugger, W ^a   Dichgans, J ^a   Weller, M ^a,c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Apoptosis; Cancer chemotherapy; Cell cycle; Differentiation; p53

Indexed keywords

ANTILEUKEMIC AGENT; PROTEIN BAX; PROTEIN P21; PROTEIN P53;

ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE; CELL DIFFERENTIATION; CELL STRAIN K 562; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SENSITIVITY; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LEUKEMIA CELL LINE; MITOSIS INHIBITION; MYELOID LEUKEMIA; PRIORITY JOURNAL; TEMPERATURE; TUMOR SUPPRESSOR GENE;

EID: 0030722470     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400824     Document Type: Article

References (14)

1. Selivanowa G, Wiman KG. p53: a cell cycle regulator activated by DNA damage. Adv Cancer Res 1995; 66: 143-180.
2. El-Deiry WS, Harper JW, O'Connor PM, Velculesco VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW, Vogelstein B. WAF1/CIP1 is induced in p53 mediated G1 arrest and apoptosis. Cancer Res 1994; 54: 1169-1174.
3. Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace Jr AJ. A mammalian cell cycle check point pathway utilizing p53 and GADD45 with proliferating cell nuclear antigen. Cell 1992; 71: 587-597.
4. Smith ML, Chen IT, Zhan Q, Bae I, Chen CY, Gilmer TM, Kastan MB, O'Connor PM, Fornace AJ. Interaction of the p53 regulated protein GADD45 with proliferating cell nuclear antigen. Science 1994; 266: 1376-1380.
5. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-299.
6. Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 1994; 54: 3131-3135.
7. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9: 293-299.
8. Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild-type p53 activity. EMBO J 1995; 12: 461-468.
9. Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang WW, Kruzel E, Radinski R. Wild-type human p53 and a temperature sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 1995; 15: 3032-3040.
10. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991; 352: 345-347.
11. Eastham JA, Hall SJ, Sehgal I, Wang J, Timme TL, Yang G, Connell Crowley L, Elledge SJ, Zhang WW, Harper JW, Thompson TC. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 1995; 55: 5151-5155.
12. Liu TJ, El-Naggar AK, McDonnell TJ, Steck KD, Wang M, Taylor DL, Clayman GL. Apoptosis induction mediated by wild type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res 1995; 55: 3117-3122.
13. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-967.
14. Blagosklonny MV, El-Deiry WS. In vitro evaluation of a p53-expressing adenovirus as an anticancer drug. Int J Cancer 1996; 67: 386-392.